메뉴 건너뛰기




Volumn 34, Issue 3, 2013, Pages 141-154

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

Author keywords

anti cancer drugs; patients with cancer; pharmacokinetics; physiologically based pharmacokinetics; Simcyp

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; ALBUMIN; CYTOCHROME P450 3A; DOCETAXEL; IMATINIB; MIDAZOLAM; OMEPRAZOLE; OROSOMUCOID; PENBUTOLOL; PI 88; RALTITREXED; SAQUINAVIR; SUNITINIB; TIPIFARNIB; TOPOTECAN; VOROZOLE;

EID: 84876284544     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1830     Document Type: Article
Times cited : (86)

References (50)
  • 2
    • 84862777920 scopus 로고    scopus 로고
    • The role of physiologically based pharmacokinetic modeling in regulatory review
    • Huang SM, Rowland M,. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin Pharmacol Ther 2012; 91 (3): 542-549.
    • (2012) Clin Pharmacol Ther , vol.91 , Issue.3 , pp. 542-549
    • Huang, S.M.1    Rowland, M.2
  • 3
    • 67649392513 scopus 로고    scopus 로고
    • A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates
    • Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
    • (2009) Drug Metab Pharmacokinet , vol.24 , pp. 53-75
    • Jamei, M.1    Dickinson, G.L.2    Rostami-Hodjegan, A.3
  • 4
    • 78951482203 scopus 로고    scopus 로고
    • Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review
    • Zhao P, Zhang L, Grillo JA, et al,. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89: 259-267.
    • Clin Pharmacol Ther , vol.89 , pp. 259-267
    • Zhao, P.1    Zhang, L.2    Grillo, J.A.3
  • 5
    • 0028124656 scopus 로고
    • Effect of age and disease on two drug binding proteins: Albumin and alpha-1-acid glycoprotein
    • Woo J, Chan HS, Or KH, Arumanayagam M,. Effect of age and disease on two drug binding proteins: albumin and alpha-1-acid glycoprotein. Clin Biochem 1994; 27: 289-292.
    • (1994) Clin Biochem , vol.27 , pp. 289-292
    • Woo, J.1    Chan, H.S.2    Or, K.H.3    Arumanayagam, M.4
  • 6
    • 23944497385 scopus 로고    scopus 로고
    • Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women
    • Engeland A, Tretli S, Austad G, Bjorge T,. Height and body mass index in relation to colorectal and gallbladder cancer in two million Norwegian men and women. Cancer Causes Control 2005; 16: 987-996.
    • (2005) Cancer Causes Control , vol.16 , pp. 987-996
    • Engeland, A.1    Tretli, S.2    Austad, G.3    Bjorge, T.4
  • 7
    • 79958703775 scopus 로고    scopus 로고
    • Cancer screening in older adults: What to do when we don't know
    • Alibhai SMH, and, Horgan AM,. Cancer screening in older adults: What to do when we don't know. Journal of Geriatric Oncology 2011; 2 (3): 149-160.
    • (2011) Journal of Geriatric Oncology , vol.2 , Issue.3 , pp. 149-160
    • Alibhai, S.M.H.1    Horgan, A.M.2
  • 8
    • 0023690101 scopus 로고
    • Drug binding to human alpha-1-acid glycoprotein in health and disease
    • Kremer JM, Wilting J, Janssen LH,. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 1-47.
    • (1988) Pharmacol Rev , vol.40 , pp. 1-47
    • Kremer, J.M.1    Wilting, J.2    Janssen, L.H.3
  • 10
    • 0021200499 scopus 로고
    • Effect of age and sex on the plasma binding of acidic and basic drugs
    • Verbeeck RK, Cardinal JA, Wallace SM,. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27: 91-97.
    • (1984) Eur J Clin Pharmacol , vol.27 , pp. 91-97
    • Verbeeck, R.K.1    Cardinal, J.A.2    Wallace, S.M.3
  • 11
    • 0019220256 scopus 로고
    • Disease-induced changes in the plasma binding of basic drugs
    • Piafsky KM,. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980; 5: 246-262.
    • (1980) Clin Pharmacokinet , vol.5 , pp. 246-262
    • Piafsky, K.M.1
  • 12
    • 0034894719 scopus 로고    scopus 로고
    • Human alpha-1-glycoprotein and its interactions with drugs
    • Israili ZH, Dayton PG,. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33: 161-235.
    • (2001) Drug Metab Rev , vol.33 , pp. 161-235
    • Israili, Z.H.1    Dayton, P.G.2
  • 14
    • 33745130722 scopus 로고    scopus 로고
    • Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
    • Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, Rostami-Hodjegan A,. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006; 36: 473-497.
    • (2006) Xenobiotica , vol.36 , pp. 473-497
    • Howgate, E.M.1    Rowland Yeo, K.2    Proctor, N.J.3    Tucker, G.T.4    Rostami-Hodjegan, A.5
  • 15
    • 33745181651 scopus 로고    scopus 로고
    • Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences
    • Inoue S, Howgate EM, Rowland-Yeo K, et al,. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 2006; 36: 499-513.
    • (2006) Xenobiotica , vol.36 , pp. 499-513
    • Inoue, S.1    Howgate, E.M.2    Rowland-Yeo, K.3
  • 17
    • 7444242095 scopus 로고    scopus 로고
    • Bicalutamide: Clinical pharmacokinetics and metabolism
    • Cockshott ID,. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004; 43: 855-878.
    • (2004) Clin Pharmacokinet , vol.43 , pp. 855-878
    • Cockshott, I.D.1
  • 18
    • 79959584649 scopus 로고    scopus 로고
    • NCT01110291: Induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer
    • Hilli J, Sailas L, Jyrkkio S, Pyrhonen S, Laine K,. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol 2011; 67: 1353-1362.
    • (2011) Cancer Chemother Pharmacol , vol.67 , pp. 1353-1362
    • Hilli, J.1    Sailas, L.2    Jyrkkio, S.3    Pyrhonen, S.4    Laine, K.5
  • 19
    • 76149087823 scopus 로고    scopus 로고
    • The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects
    • Stroh M, Dishy V, Radziszewski W, et al,. The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects. Am J Ther 2010; 17: 53-60.
    • (2010) Am J Ther , vol.17 , pp. 53-60
    • Stroh, M.1    Dishy, V.2    Radziszewski, W.3
  • 20
    • 77955262859 scopus 로고    scopus 로고
    • An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers
    • Tomkinson HK, Kemp JV, Wollseifen T, Morris T, Oliver SD,. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. Clin Ther 2010; 32: 1372-1386.
    • (2010) Clin Ther , vol.32 , pp. 1372-1386
    • Tomkinson, H.K.1    Kemp, J.V.2    Wollseifen, T.3    Morris, T.4    Oliver, S.D.5
  • 21
    • 77955549620 scopus 로고    scopus 로고
    • Effect of glycyrrhizin on the activity of CYP3A enzyme in humans
    • Tu JH, He YJ, Chen Y, et al,. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol 2010; 66: 805-810.
    • (2010) Eur J Clin Pharmacol , vol.66 , pp. 805-810
    • Tu, J.H.1    He, Y.J.2    Chen, Y.3
  • 23
    • 0029988526 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: Role of altered protein binding
    • Aguirre C, Troconiz IF, Valdivieso A, et al,. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Res Commun Mol Pathol Pharmacol 1996; 92: 53-72.
    • (1996) Res Commun Mol Pathol Pharmacol , vol.92 , pp. 53-72
    • Aguirre, C.1    Troconiz, I.F.2    Valdivieso, A.3
  • 24
    • 3843133122 scopus 로고    scopus 로고
    • Population pharmacokinetics of APOMINE: A meta-analysis in cancer patients and healthy males
    • Bonate PL, Floret S, Bentzen C,. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males. Br J Clin Pharmacol 2004; 58: 142-155.
    • (2004) Br J Clin Pharmacol , vol.58 , pp. 142-155
    • Bonate, P.L.1    Floret, S.2    Bentzen, C.3
  • 25
    • 65249087328 scopus 로고    scopus 로고
    • A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients
    • Houk BE, Bello CL, Kang D, Amantea M,. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-2506.
    • (2009) Clin Cancer Res , vol.15 , pp. 2497-2506
    • Houk, B.E.1    Bello, C.L.2    Kang, D.3    Amantea, M.4
  • 28
    • 0031847284 scopus 로고    scopus 로고
    • Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients
    • Piotrovsky VK, Huang ML, Van Peer A, Langenaecken C,. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Cancer Chemother Pharmacol 1998; 42: 221-228.
    • (1998) Cancer Chemother Pharmacol , vol.42 , pp. 221-228
    • Piotrovsky, V.K.1    Huang, M.L.2    Van Peer, A.3    Langenaecken, C.4
  • 29
    • 26944440101 scopus 로고    scopus 로고
    • The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics
    • Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T,. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 2005; 44: 1179-1189.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 1179-1189
    • Ishizawa, Y.1    Yasui-Furukori, N.2    Takahata, T.3    Sasaki, M.4    Tateishi, T.5
  • 30
    • 0028970499 scopus 로고
    • Population pharmacokinetics of docetaxel during phase i studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation
    • Launay-Iliadis MC, Bruno R, Cosson V, et al,. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995; 37: 47-54.
    • (1995) Cancer Chemother Pharmacol , vol.37 , pp. 47-54
    • Launay-Iliadis, M.C.1    Bruno, R.2    Cosson, V.3
  • 31
    • 57349120552 scopus 로고    scopus 로고
    • Covariation of human microsomal protein per gram of liver with age: Absence of influence of operator and sample storage may justify interlaboratory data pooling
    • Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A,. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 2008; 36: 2405-2409.
    • (2008) Drug Metab Dispos , vol.36 , pp. 2405-2409
    • Barter, Z.E.1    Chowdry, J.E.2    Harlow, J.R.3    Snawder, J.E.4    Lipscomb, J.C.5    Rostami-Hodjegan, A.6
  • 32
    • 78751558968 scopus 로고    scopus 로고
    • The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients
    • Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J,. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50: 99-110.
    • (2011) Clin Pharmacokinet , vol.50 , pp. 99-110
    • Ulldemolins, M.1    Roberts, J.A.2    Rello, J.3    Paterson, D.L.4    Lipman, J.5
  • 34
    • 33746678595 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer
    • Lu JF, Eppler SM, Wolf J, et al,. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80: 136-145.
    • (2006) Clin Pharmacol Ther , vol.80 , pp. 136-145
    • Lu, J.F.1    Eppler, S.M.2    Wolf, J.3
  • 35
    • 79954571612 scopus 로고    scopus 로고
    • Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding
    • Graham RA, Lum BL, Cheeti S, et al,. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2012; 17: 2512-2520.
    • (2012) Clin Cancer Res , vol.17 , pp. 2512-2520
    • Graham, R.A.1    Lum, B.L.2    Cheeti, S.3
  • 36
    • 0024310292 scopus 로고
    • Clinical relevance of alpha 1 acid glycoprotein in health and disease
    • Routledge PA,. Clinical relevance of alpha 1 acid glycoprotein in health and disease. Prog Clin Biol Res 1989; 300: 185-198.
    • (1989) Prog Clin Biol Res , vol.300 , pp. 185-198
    • Routledge, P.A.1
  • 37
    • 0033929869 scopus 로고    scopus 로고
    • Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer
    • Duche JC, Urien S, Simon N, Malaurie E, Monnet I, Barre J,. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000; 33: 197-202.
    • (2000) Clin Biochem , vol.33 , pp. 197-202
    • Duche, J.C.1    Urien, S.2    Simon, N.3    Malaurie, E.4    Monnet, I.5    Barre, J.6
  • 38
    • 62949175363 scopus 로고    scopus 로고
    • Lack of effect of subject posture on intravenous midazolam clearance: Implications for hepatic cytochrome P450 3A phenotyping
    • Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr,. Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. Br J Clin Pharmacol 2009; 67: 374-375.
    • (2009) Br J Clin Pharmacol , vol.67 , pp. 374-375
    • Ma, J.D.1    Nafziger, A.N.2    Mylott, W.3    Haughey, D.B.4    Rocci, Jr.M.L.5    Bertino, Jr.J.S.6
  • 39
    • 19944427867 scopus 로고    scopus 로고
    • Factors affecting cytochrome P-450 3A activity in cancer patients
    • Baker SD, van Schaik RH, Rivory LP, et al,. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004; 10: 8341-8350.
    • (2004) Clin Cancer Res , vol.10 , pp. 8341-8350
    • Baker, S.D.1    Van Schaik, R.H.2    Rivory, L.P.3
  • 40
    • 0141672041 scopus 로고    scopus 로고
    • The binding of HIV-1 protease inhibitors to human serum proteins
    • Schon A, del Mar Ingaramo M, Freire E,. The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem 2003; 105: 221-230.
    • (2003) Biophys Chem , vol.105 , pp. 221-230
    • Schon, A.1    Del Mar Ingaramo, M.2    Freire, E.3
  • 42
    • 0022539064 scopus 로고
    • Plasma drug binding: Implications for anesthesiologists
    • Wood M,. Plasma drug binding: implications for anesthesiologists. Anesth Analg 1986; 65: 786-804.
    • (1986) Anesth Analg , vol.65 , pp. 786-804
    • Wood, M.1
  • 45
    • 34548787904 scopus 로고    scopus 로고
    • Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study
    • Launay-Vacher V, Oudard S, Janus N, et al,. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384.
    • (2007) Cancer , vol.110 , pp. 1376-1384
    • Launay-Vacher, V.1    Oudard, S.2    Janus, N.3
  • 46
    • 84859803615 scopus 로고    scopus 로고
    • Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients
    • Takahashi N, Miura M, Niioka T, Sawada K,. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol 2012; 69: 999-1004.
    • (2012) Cancer Chemother Pharmacol , vol.69 , pp. 999-1004
    • Takahashi, N.1    Miura, M.2    Niioka, T.3    Sawada, K.4
  • 47
    • 0028307740 scopus 로고
    • P-glycoprotein, multidrug resistance and tumor progression
    • Bradley G, Ling V,. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13: 223-233.
    • (1994) Cancer Metastasis Rev , vol.13 , pp. 223-233
    • Bradley, G.1    Ling, V.2
  • 48
    • 33746881712 scopus 로고    scopus 로고
    • Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
    • Widmer N, Decosterd LA, Csajka C, et al,. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006; 62: 97-112.
    • (2006) Br J Clin Pharmacol , vol.62 , pp. 97-112
    • Widmer, N.1    Decosterd, L.A.2    Csajka, C.3
  • 49
    • 1942455391 scopus 로고    scopus 로고
    • Population pharmacokinetics of raltitrexed in patients with advanced solid tumours
    • Blair EY, Rivory LP, Clarke SJ, McLachlan AJ,. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. Br J Clin Pharmacol 2004; 57: 416-426.
    • (2004) Br J Clin Pharmacol , vol.57 , pp. 416-426
    • Blair, E.Y.1    Rivory, L.P.2    Clarke, S.J.3    McLachlan, A.J.4
  • 50
    • 18344394148 scopus 로고    scopus 로고
    • Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors
    • Mould DR, Holford NH, Schellens JH, et al,. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002; 71: 334-348.
    • (2002) Clin Pharmacol Ther , vol.71 , pp. 334-348
    • Mould, D.R.1    Holford, N.H.2    Schellens, J.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.